MetLife Investment Management
CTMX icon

MetLife Investment Management’s CytomX Therapeutics CTMX Stock Holding History

MetLife Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Buy
+104,635
New +$400K ﹤0.01% 2064
2022
Q2 		– Sell
-17,692
Closed -$47.2K – 2871
2022
Q1 		$47.2K Sell
17,692
-6,754
-28% -$25.9K ﹤0.01% 2680
2021
Q4 		$106K Buy
24,446
+14,566
+147% +$85.3K ﹤0.01% 2387
2021
Q3 		$50.3K Sell
9,880
-16,228
-62% -$86.9K ﹤0.01% 2532
2021
Q2 		$165K Buy
26,108
+20,846
+396% +$162K ﹤0.01% 2269
2021
Q1 		$40.7K Sell
5,262
-9,764
-65% -$77.3K ﹤0.01% 2286
2020
Q4 		$98.4K Hold
15,026
– – ﹤0.01% 2227
2020
Q3 		$99.9K Sell
15,026
-12,276
-45% -$91K ﹤0.01% 2211
2020
Q2 		$227K Hold
27,302
– – ﹤0.01% 1831
2020
Q1 		$209K Hold
27,302
– – ﹤0.01% 1674
2019
Q4 		$227K Hold
27,302
– – ﹤0.01% 1913
2019
Q3 		$201K Hold
27,302
– – ﹤0.01% 1939
2019
Q2 		$306K Sell
27,302
-27,568
-50% -$289K ﹤0.01% 1772
2019
Q1 		$590K Buy
54,870
+36,580
+200% +$541K ﹤0.01% 1968
2018
Q4 		$276K Hold
18,290
– – ﹤0.01% 1732
2018
Q3 		$338K Hold
18,290
– – ﹤0.01% 1782
2018
Q2 		$418K Buy
18,290
+4,831
+36% +$123K ﹤0.01% 1515
2018
Q1 		$383K Buy
13,459
+1,860
+16% +$53.1K ﹤0.01% 1538
2017
Q4 		$245K Buy
+11,599
New +$241K ﹤0.01% 1823

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

MetLife Investment Management's CTMX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 104,635 shares worth $392K. The stake represents ﹤0.01% of the portfolio and ranks #2064 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in CTMX as recently as Q1 2022.

MetLife Investment Management first reported a position in CTMX in Q4 2017 and has held it in 19 quarters since. The position peaked at $590K in Q1 2019. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • MetLife Investment Management held 104,635 shares of CytomX Therapeutics worth $392K as of Q2 2026.
  • CytomX Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2064 holding.
  • MetLife Investment Management first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 19 quarters since.
  • MetLife Investment Management's CytomX Therapeutics position peaked at $590K in Q1 2019.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.